Fourpath Capital Management’s Eli Lilly LLY Stock Holding History

Fourpath Capital Management’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5M	Sell	13,623 -1,590	-10%	-$1.61M	1.8%	11
2025 Q4	$16.3M	Sell	15,213 -21	-0.1%	-$20.1K	2.24%	9
2025 Q3	$11.6M	Sell	15,234 -184	-1%	-$137K	1.65%	19
2025 Q2	$12M	Sell	15,418 -288	-2%	-$224K	1.89%	11
2025 Q1	$13M	Sell	15,706 -199	-1%	-$166K	2.26%	8
2024 Q4	$12.3M	Sell	15,905 -2,479	-13%	-$2.05M	2.27%	9
2024 Q3	$16.3M	Buy	18,384 +18,049	+5,388%	+$16.2M	3%	4
2024 Q2	$303K	Buy	335 +1	+0.3%	+$800	0.22%	91
2024 Q1	$260K	Buy	+334	New	+$238K	0.18%	108

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $84.5B AUM 11.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fourpath Capital Management's LLY Position: Q1 2026 in Review

Fourpath Capital Management reduced its Eli Lilly (LLY) stake by 10% in Q1 2026, selling an estimated $1.61M and leaving 13,623 shares worth $12.5M. The position accounts for 1.8% of the portfolio, ranked #11.

Fourpath Capital Management first reported a position in LLY in Q1 2024 and has held it in 9 quarters since. The position peaked at $16.3M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

Fourpath Capital Management held 13,623 shares of Eli Lilly worth $12.5M as of Q1 2026.
Fourpath Capital Management sold 1,590 Eli Lilly shares in Q1 2026, an estimated $1.61M.
Eli Lilly made up 1.8% of Fourpath Capital Management's portfolio in Q1 2026, its #11 holding.
Fourpath Capital Management first reported a position in Eli Lilly in Q1 2024 and has held it in 9 quarters since.
Fourpath Capital Management's Eli Lilly position peaked at $16.3M in Q4 2025.
4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Fourpath Capital Management's 13F filing for Q1 2026, filed 1 May 2026.